Business Wire

Veristat Named Top Patient Recruitment Company 2020 by Pharma Tech Outlook

Share

Veristat, a global clinical research organization, was named among the Top Patient Recruitment Companies of 2020 by Pharma Tech Outlook. With over 26 years’ experience partnering with start-up to mid-size biotech and pharmaceutical companies, Veristat excels in supporting complex trials across a wide range of therapeutic areas. Always taking a patient-centric approach, the company is highly innovative and formulates flexible solutions that benefit patients and attract them to participate in clinical trials.

In today’s digital world, patients proactively participate in their health plans and seek information on various diseases and treatments online,” stated Shaheen Limbada, Executive Vice President, Global Clinical Operations at Veristat, “Realizing this, we’ve focused on targeting the potential and intended participants for trials through digital media and online platforms. Veristat curates highly relevant and appropriate patient populations by leveraging in-house, customized marketing, and search engine optimization strategies. These strategies improve patient recruitment and retention success rates for trials efficiently and cost-effectively.”

Responding rapidly to the COVID-19 situation and taking a thoughtful scientific approach towards it, Veristat has expanded virtual ecosystems for clients specific to their needs ensuring continuity of ongoing and new clinical trials. The company has developed a “rescue study methodology,” comprised of a series of non-conventional good clinical practice (GCP) compliant tactics for supporting trials. By setting up virtual sites, Veristat ensures the continuity of studies by allowing patients to participate in trials remotely through telemedicine patient portals and at-home visits. Access to the required equipment and medical supplies promptly enabled patients to continue the programs and clients to begin new programs. The company safeguarded patient recruitment throughout the pandemic with its rescue strategies. This included web console technology for staff to interact, patient portals for patients and physicians to communicate via telemedicine, and secure document exchange portals for the collection of study documentation.

Applying knowledge from the various COVID-19 trials that they have conducted, Veristat established a COVID taskforce to centralize the lessons learned and to leverage the most successful approaches on the different trials to focus the trial activities to achieve the highest enrollment. “We are continuously working on advancing the trials in a productive and impactful way unique for each clinical setting to ensure we respond to a highly elevated sense of urgency due to the pandemic and evolving client needs,” stated Patrick Flanagan, Chief Executive Officer at Veristat.

Click here for access to the full interview on Pharma Tech Outlook.

About Veristat:

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last ten years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, cell and gene therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com.

Contact information

Veristat Contact:
Lauren Willis, Marketing Manager
marketing@veristat.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nottinghamshire County Council Renews Support Agreement With Rimini Street for Its Mission-Critical SAP Applications21.1.2021 15:00:00 CETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Nottinghamshire County Council (NCC) has renewed its agreement with Rimini Street for Support of its SAP ECC 6.0 and SAP Business Objects software. NCC first switched to Rimini Street in 2017, achieving substantial savings in maintenance fees over the last three years, as well as related savings in avoided upgrades, process efficiencies and customization support, included at no additional charge. At a time of significant strain on public sector budgets, NCC renewed its agreement with Rimini Street to continue to achieve these essential savings as the local authority seeks to drive efficiencies in its back-office IT systems. Additionally, NCC has the reassurance that their software systems will be supported for a guaranteed minimum of 15 years from the time they swi

Alvarez & Marsal Announces 2021 Managing Director Promotions21.1.2021 15:00:00 CETPress release

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 37 professionals from across Benelux, Brazil, Germany, India, Italy, Sweden, the United Kingdom and the United States to the position of Managing Director. John Suckow, A&M’s Chief Operating Officer, stated, “For over 37 years, A&M professionals have delivered leadership, action and results to our clients. In this unique and challenging year, our leaders have not wavered, and we have achieved extraordinary professional growth and success. We congratulate all of our newly promoted Managing Directors and applaud their commitment to A&M's core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity.” Brazil Henrique Biscolla, São Paulo Eduardo Gallardo, São Paulo Emerson Santana, São Paulo Corporate Performance Improvement Tres Evans, Dallas Michael Nelson, Chicago Kristin Shelley, Dallas Global Disputes and Investigations Nikki Coles, London Europe - Performance

XClinical to Merge with Carenity and Fortress Medical Systems Forming a New Data Science Company Serving Life Science Markets Worldwide21.1.2021 14:00:00 CETPress release

XClinical, a leading vendor of eClinical software has announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system. All three companies are long-established, leading providers in their respective markets. The group is financed by German Private Equity firm BID Equity. Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology. The group brings best in class data science and eClinical software solutions together, delivering end-to-end coverage of the clinical development process for their 150+ customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China. Biopharma, Medical Device as well as Academic sponsors and CROs worldwide will benefit from progressive and cost-efficient solutions such as feasibility studies, Real World Evidence data collection, patient

HempFusion Announces Large-Scale Distribution Agreement with Fullscript.com to Launch Doctor Practitioner Sales Channel21.1.2021 13:01:00 CETPress release

HempFusion Wellness Inc. (TSX:CBD.U) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has entered into a large-scale distribution agreement with Fullscript.com (“Fullscript”), a leading eCommerce platform that allows health professionals to dispense professional-grade natural health products. Fullscript is one of the largest distributors in the category, providing nutritional supplements to over 80,000 practitioners and over 600,000 patients across the United States and Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005282/en/ Total Care Daily Probiotic from Biome Research (Photo: Business Wire) This agreement signifies HempFusion’s strategic launch into the doctor practitioner sales channel. HempFusion’s seven Biome Research SKUs will be available to ship from Fullscript distribution centers starting Febr

Tinubu® Square Announces Technological Collaboration With Microsoft21.1.2021 13:00:00 CETPress release

Tinubu Square, the market leader for enterprise software solutions to Credit and Surety Insurers, announces cooperation with Microsoft, the leading provider in Business Intelligence solutions. Olivier Placca, Tinubu Square co-founder and Deputy CEO declares: “This cooperation is strategic for Tinubu Square to continue to offer carriers best-in-class technologies in the long run using the strength of Power BI across all business lines of our SaaS-based, end-to-end Enterprise Solution Platform. Our primary objective is answering our customers’ needs. Integrating Power BI to our Credit Insurance and Surety Platform offers them key benefits such as powerful insights, a scalable solution and settings on-the-fly. To take full advantage of our Business Intelligence capabilities, customers can tailor their own reports using a specifically designed Tinubu® CIS data model, increasing efficiency and data relevance. Offer Sadey, Chief Technical Officer at Tinubu Square, explains: “Before choosing

numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics21.1.2021 12:00:00 CETPress release

Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the numares brand AXINON®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005438/en/ numare's AI-driven, NMR-based diagnostic platform AXINON is easy to operate by laboratory technicians. (Photo: Business Wire) Based on a longstanding collaboration between the two companies, the agreement creates a combination of numares’ expertise in leveraging metabolomics for software-based diagnostics with world-leading nuclear magnetic resonance (NMR) technology from Bruker. This leads to more rapid, accurate and persona

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients21.1.2021 11:14:00 CETPress release

AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study. “We are pleased to report the achievement of this critical milestone, and AriBio is looking forward to announcing the topline results by the end of Q1’2021. Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial. We are extremely grateful to our study participants, their family members and healthcare professionals who worked tirelessly to complete the primary assessments of the study,” said James Rock, Senior Vice President of Clinical Operations. AriBio offered an optional 6-month extension phase of the study, where

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom